EGFR and non-small cell lung carcinoma: Intrinsic and acquired drug resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) is the main cause of treatment failure in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) [1–3].